Fluoroquinolone antimicrobial agents in the treatment of prostatitis and recurrent urinary tract infections in men. 2004

F M E Wagenlehner, and K G Naber
Urologic Clinic, Hospital St. Elisabeth Straubing, St. Elisabeth Str. 23, D-94315 Straubing, Germany.

Chronic bacterial prostatitis is the most frequent cause for recurrent urinary tract infection in young and middle-aged men. The selection of an appropriate antimicrobial agent that has optimal pharmacokinetics for urine and prostatic secretion and tissue is important in both entities. Fluoroquinolones possess several pharmacologic characteristics that favor them for treatment of urinary tract infection and prostatitis. The pharmacokinetics of fluoroquinolones and the theoretical background of drug penetration into the prostate are outlined. Analyzing the concentrations of various fluoroquinolones in urine, prostatic and seminal fluid, and in prostatic tissue, it becomes obvious that the fluoroquinolones differ in plasma concentrations and in their concentrations at these sites. Nevertheless, overall, the concentrations at the site of infection of most of the fluoroquinolones should be sufficient for the treatment of chronic bacterial prostatitis and vesiculitis and recurrent urinary tract infection in men caused by susceptible pathogens.

UI MeSH Term Description Entries
D008297 Male Males
D011472 Prostatitis Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment. Acute Bacterial Prostatitis,Asymptomatic Inflammatory Prostatitis,Chronic Bacterial Prostatitis,Chronic Prostatitis with Chronic Pelvic Pain Syndrome,Acute Bacterial Prostatitides,Asymptomatic Inflammatory Prostatitides,Bacterial Prostatitides, Acute,Bacterial Prostatitides, Chronic,Bacterial Prostatitis, Acute,Bacterial Prostatitis, Chronic,Chronic Bacterial Prostatitides,Inflammatory Prostatitis, Asymptomatic,Prostatitides,Prostatitides, Chronic Bacterial
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001424 Bacterial Infections Infections by bacteria, general or unspecified. Bacterial Disease,Bacterial Infection,Infection, Bacterial,Infections, Bacterial,Bacterial Diseases
D014552 Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA. Infection, Urinary Tract,Infections, Urinary Tract,Tract Infection, Urinary,Tract Infections, Urinary,Urinary Tract Infection
D017699 Pelvic Pain Pain in the pelvic region of genital and non-genital origin. Pain, Pelvic,Pains, Pelvic,Pelvic Pains
D024841 Fluoroquinolones A group of QUINOLONES with at least one fluorine atom and a piperazinyl group. Fluoroquinolone
D024881 Drug Resistance, Bacterial The ability of bacteria to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance, Bacterial,Antibacterial Drug Resistance

Related Publications

F M E Wagenlehner, and K G Naber
November 1985, Seminars in urology,
F M E Wagenlehner, and K G Naber
January 1990, Urology,
F M E Wagenlehner, and K G Naber
January 2019, Current pharmaceutical design,
F M E Wagenlehner, and K G Naber
November 1987, Mayo Clinic proceedings,
F M E Wagenlehner, and K G Naber
March 1983, Mayo Clinic proceedings,
F M E Wagenlehner, and K G Naber
January 1968, Nederlands tijdschrift voor geneeskunde,
F M E Wagenlehner, and K G Naber
April 2017, Revue medicale suisse,
F M E Wagenlehner, and K G Naber
April 2004, Journal of chemotherapy (Florence, Italy),
Copied contents to your clipboard!